Cargando…

The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review

Levomilnacipran, the more active enantiomer of the serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in the US for the treatment of major depressive disorder (MDD). The drug was developed as an extended release (ER) capsule formulation to allow for once-daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruno, Antonio, Morabito, Paolo, Spina, Edoardo, Muscatello, Maria Rosaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825949/ https://www.ncbi.nlm.nih.gov/pubmed/26572745 http://dx.doi.org/10.2174/1570159X14666151117122458

Ejemplares similares

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis, Gregory M, et al.
Publicado: (2015)

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
por: Freeman, Marlene P., et al.
Publicado: (2016)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2016)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang, Qunlian, et al.
Publicado: (2016)

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
por: Montgomery, Stuart A., et al.
Publicado: (2014)

Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study
por: Durgam, Suresh, et al.
Publicado: (2019)

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
por: Sambunaris, Angelo, et al.
Publicado: (2014)

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
por: Wesnes, Keith A., et al.
Publicado: (2017)

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
por: Chen, Laishun, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
por: Gommoll, Carl P., et al.
Publicado: (2014)

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
por: Sambunaris, Angelo, et al.
Publicado: (2014)

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
por: Montgomery, Stuart A., et al.
Publicado: (2014)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre, Roger S
Publicado: (2017)

When Fathers Begin to Falter: A Comprehensive Review on Paternal Perinatal Depression
por: Bruno, Antonio, et al.
Publicado: (2020)

Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review
por: Fiorillo, Andrea, et al.
Publicado: (2018)

Negative Emotions in Skin Disorders: A Systematic Review
por: Mento, Carmela, et al.
Publicado: (2020)

Disposition and metabolism of [(14)C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats
por: Brunner, Valérie, et al.
Publicado: (2015)

Combining intensive repetitive transcranial magnetic stimulation with neurofeedback in a case of treatment-resistant depression
por: Bruno, Antonio, et al.
Publicado: (2021)

Role of Spirituality in the Management of Major Depression and Stress-Related Disorders
por: Varghese, Sajoy P., et al.
Publicado: (2021)

Role of yoga in stress management and implications in major depression disorder
por: R, Padmavathi, et al.
Publicado: (2023)

Prioritization and comprehensive analysis of genes related to major depressive disorder
por: Liu, Yi, et al.
Publicado: (2019)

The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
por: Barlati, Stefano, et al.
Publicado: (2023)

The Relationship between Alexithymia, Anxiety, Depression, and Internet Addiction Severity in a Sample of Italian High School Students
por: Scimeca, Giuseppe, et al.
Publicado: (2014)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Baune, Bernhard T
Publicado: (2008)

IL-33 in Mental Disorders
por: Pandolfo, Gianluca, et al.
Publicado: (2021)

A Review of the Role of Social Cognition in Major Depressive Disorder
por: Weightman, Michael James, et al.
Publicado: (2014)

Psychological Impact of Pro-Anorexia and Pro-Eating Disorder Websites on Adolescent Females: A Systematic Review
por: Mento, Carmela, et al.
Publicado: (2021)

Emerging treatments in the management of schizophrenia – focus on sertindole
por: Muscatello, Maria Rosaria A, et al.
Publicado: (2010)

Investigating suicidality across the autistic-catatonic continuum in a clinical sample of subjects with major depressive disorder and borderline personality disorder
por: Dell’Osso, Liliana, et al.
Publicado: (2023)

Eating Disorders and Major Depression: Role of Anger and Personality
por: Giovanni, Abbate-Daga, et al.
Publicado: (2011)

The Role of Chemokines in the Pathophysiology of Major Depressive Disorder
por: Milenkovic, Vladimir M., et al.
Publicado: (2019)

The roles of extracellular vesicles in major depressive disorder
por: Li, Ying, et al.
Publicado: (2023)

Comorbidity from a Categorical to a Transdiagnostic-Dimensional Approach: New Perspectives for Researchers and Clinicians
por: Bruno, Antonio, et al.
Publicado: (2023)

A comprehensive network and pathway analysis of candidate genes in major depressive disorder
por: Jia, Peilin, et al.
Publicado: (2011)

A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER
por: Olvet, Doreen M., et al.
Publicado: (2015)

MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective
por: Ortega, Miguel A., et al.
Publicado: (2021)

Comprehensive analysis of endoplasmic reticulum stress and immune infiltration in major depressive disorder
por: Zhang, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a2scf90rjvtdlubt04n293ohhn